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to 0.886 and they all belonged to 5 factors. There was a strong relationship between 
SCS and EuroQol 5D (r  between 0.46–0.76). CONCLUSIONS: The research sug-
gests that the validity and reliability of the Turkish SCS are satisfactory and that it 
can be used in Turkey.
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CLINICO-PHARMACOLOGICAL PRESENTATION AND THE OUTCOME 
OF QUALITY OF LIFE OF PATIENTS WITH EXACERBATION OF 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Bawoh M
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OBJECTIVES: Determine quality of life of COPD patients. METHODS: The medical 
records of 300 patients with acute exacerbation of COPD who visited City Clinical 
Hospital #2, with mean age 68.5 o 4.5 male and 64.8 o 3.4 female, were retrospec-
tively reviewed. Patients were evaluated on the criteria for COPD [2006]. Socio-
 demographic data, severity of disease, co-morbidity, and use of health resources in 
the previous years were collected. SF-36 quality of life questionnaire were administered 
to all patients. RESULTS: The mean FEV1 value was 45.9 o 9.1%. The severity of the 
disease was mild in 139 (46.3%) cases, moderate in 114 (38.0%), severe in 30 
(10.0%), very severe in 17 (5.7%). With regard to the use of health resources in the 
previous year, the mean values were: visits to physician 7,27 o 1,2 and hospital admis-
sions 8,16 o 0,31. The mean SF-36 scores for patients with mild COPD in the physical 
component before and after therapy were 84.5 o 4.2 and 91.2 o 5.8 with $ % value 
(9.2 o 1.6); moderate 73.2 o 3.1 and 77.6 o 4.6 with $ % value (6.0 o 1.5); severe 
42.2 o 1.2 and 45.2 o 2.6 with $ % (4.5 o 1.4); very severe 19.8 o 2.4 and 23.5 o 
3.8 with $ % value (4.2 o 1.4). Similarly, the mean SF-36 scores on mental component 
of all groups of patients under study, ranging from mild to very severe were 69.60 o 
2.1 and 72.3 o 3.4 with $ % value (3.1 o 2.3); 54.6 o 2.2 and 56.9 o 3.7 with $ % 
value (4.2 o 1.5); 38.0 o 2.3 and 39.6 o 3.1 with $ % 3.9 o 0.8; 28.2 o 1.1 and 29.1 
o 2.4 with $ % value (4.2 o 1.3). CONCLUSIONS: Patients had an increase functional 
dynamic index ($ %) of SF-36 in the physical component, and signiﬁcant reduction 
was only seen in mental component of patients with severe and very severe cases.
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VENTILATED PATIENTS UNDER DRG 475:  
A POPULATION-BASED STUDY
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OBJECTIVES: Mechanical ventilation for acute respiratory failure is likely to be a           
reliable indicator of critical care resource requirements on a population level. Our aim 
is to analyze the costs and discharge status for patients with respiratory failure needing 
mechanical ventilation (DRG code 475) in Spain and to examine the impact of age in 
terms of hospital outcome. METHODS: From the 2004 National Hospital Discharge 
Database all records aged 16 years with a ﬁnal DRG 475 were retrieved. This DRG, 
deﬁned as “respiratory system diagnosis with mechanical ventilation”, includes three 
procedure codes and is applied to patients undergoing mechanical ventilation for a 
variable period of time. Demographic characteristics, clinical outcomes and hospital-
resources utilization were examined. An exploratory logistic regression analysis was 
performed to identify factors associated with in-hospital mortality. To depict the 
amount of resources spent to procure a given level of desired outcome (hospital sur-
vival) we determined the cost per survivor based in the average national charges for 
DRG 475. RESULTS: 4267 cases were eligible for analysis. Mean age was 64 yr, 71%            
were men and 85% medical patients. According to Charlson index, 45% of cases had 
no associated comorbidity. Overall 36% of cases required prolonged mechanical 
ventilation. In-hospital mortality was 39%. Median LOS was 14 days. Total hospital 
costs were ª 42,581,929. Multivariate logistic regression showed that age signiﬁcantly 
correlated with in-hospital mortality after adjusting for comorbidities, principal cause 
of hospital admission and duration of mechanical ventilation. An inverse relationship 
between survival rate and age was observed and this resulted in an age-related 
increased cost per survivor. CONCLUSIONS: Age has a signiﬁcant impact on out-      
comes in patients under DRG 475. These analyses will help inform health care deci-
sion-making and resource planning in the face of an ageing population. This study  
has been supported by the Spanish National ID Program (grant number STPY 
1456/07).
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OBJECTIVES: Despite different licences for the use of inhaled corticosteroids/ long 
acting beta—agonist combination products for Chronic Obstructive Pulmonary 
Disease (COPD) and asthma, anecdotal evidence suggests general practitioners pre-
scribe similar formulations and doses for both diseases. For patients with COPD, 
where the licences are more restricted, this may lead to “off-label” prescribing. The 
objective of this study was to examine the frequency and nature of “off-label” pre-
scribing of combination products in COPD patients. METHODS: This was a retro-
spective cohort study using data from the General Practice Research Database 
(GPRD), a large nationally representative UK primary care database. All combined 
salmeterol/ﬂuticasone and formoterol/budesonide prescriptions written between 
Jan 2006 and Dec 2007 for patients with a Read code for COPD were selected. 
“Off-label” prescribing was deﬁned as any formulation and/ or dose of salmeterol/
ﬂuticasone or formoterol/budesonide not licensed for COPD. The proportion of 
“off-label” prescriptions was calculated for each of the 2 treatments and “off-label” 
prescriptions were further subdivided into whether they were “off-label” with respect 
to formulation or dose. All calculations were replicated at the patient level and 
reported in relation to age, sex and smoking status. RESULTS: The analyses were 
based on a total of 21,137 COPD patients receiving combination products (salme-
terol/ﬂuticasone: 17,115; formoterol/budesonide: 4,809) between 2006–2007. 77% of 
prescriptions were “off-label”, 71% for an incorrect formulation and 6% for an 
incorrect dose. 86% of salmeterol/ﬂuticasone prescriptions were “off-label” (85% 
formulation, 1% dose) versus 37% of formoterol/budesonide prescriptions (10% 
formulation, 27% dose). The most frequently prescribed unlicensed formulations 
were salmeterol 25 mcg/ﬂuticasone 250 mcg pMDI (45%) and salmeterol 25 mcg/
ﬂuticasone 125 mcg pMDI (20%). CONCLUSIONS: “Off-label” prescribing of com-
bination therapy in COPD patients is very common in the UK. The impact of off-label 
prescribing on efﬁcacy and patient safety is unknown; “off-label” prescribing poten-
tially represents an economically wasteful prescribing practice.
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SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES— 
THE EXAMPLE OF RSV
Hampp C, Winterstein AG
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OBJECTIVES: Due to cost reaching $10,000/season, respiratory syncytial virus (RSV) 
immunoprophylaxis is limited to high-risk periods, but season determination is heavily 
debated and absolute risk varies signiﬁcantly by geographic location. We present 
monthly RSV incidence rates to estimate absolute burden of disease and numbers 
needed to treat (NNT) to provide an alternative to a dichotomous season deﬁnition. 
METHODS: Medicaid fee-for service recipients 2 years old from California and 
Florida (1999–2004) were selected if they met high-risk criteria for RSV infections 
(chronic lung disease or congenital heart disease based on ICD-9 codes, or prematurity 
up to 32 weeks’ gestational age based on birth certiﬁcates). Monthly RSV hospitaliza-
tion rates were broken down by recipients’ age and adjusted for the effects of immu-
noprophylaxis. NNTs were calculated as inverse of the absolute risk reduction (based 
on relative risk reduction from clinical trial data: 50%). Results in Florida were sepa-
rated in 5 surveillance regions. RESULTS: California showed a very distinct season 
from December–March with almost zero viral activity outside. NNTs were smallest 
in February (50) but increased with increasing age. In Florida, no months had zero 
activity; however, NNTs were never below 125, regardless of age. Among children 1 
year, the lowest NNT was 252 [95% CI: 129–5,875] and NNTs exceeded 500 for 8 
months (January–August). While the northern regions showed a short, distinct season, 
the southern regions experienced prolonged activity, most obvious in the southeast. 
Yet, April through July in the southwest and May/June in the southeast showed NNTs 
exceeding 650 while the winter months had a peak activity that was comparable to 
other regions. CONCLUSIONS: NNTs can address differences in burden of disease 
during the RSV season and between geographic regions and assure equitable access 
to prophylaxis. Reduced RSV incidence in the second year of life should be incorpo-
rated in decisions for immunoprophylaxis.
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OBJECTIVES: Tobacco has been identiﬁed as a major risk factor for lung cancer, 
heart disease, and respiratory disease. Adults rarely visit their physicians for preventive 
care. But surveys have shown that more than half of adult smokers see a dentist each 
year for preventive care. This may put dentists in a better position to implement 
tobacco cessation interventions. The aim of the study was to investigate the tobacco 
cessation interventions conducted by dental practitioners in Japan. METHODS: The 
study used a survey mailed to dentists (n  1489) in three prefectures (Tokyo, Iwate, 
Yamanashi) asking about the practitioners’ tobacco cessation activities, patient demo-
graphic characteristics, barriers to counseling, and attitudes towards tobacco in 2008. 
RESULTS: The response rate was 57% (n  847). Dentists advised 22% of patients 
to cease tobacco. More than half of them used a pamphlet or other printed materials. 
However, nicotine replacement therapy was prescribed infrequently (nicotine patches 
in 3.2% and nicotine gum in 2.2% of patients). Asked whether dentists should 
perform tobacco cessation interventions in their ofﬁces, 76% said yes. The main 
barrier to cessation counseling was insufﬁcient time, followed by a lack of knowledge 
and tobacco cessation specialists to whom to refer patients. 85% of respondents had 
no education or training in promoting tobacco cessation. Twenty-two percent of all 
respondents were smokers. CONCLUSIONS: Few dentists perform tobacco cessation 
interventions in their ofﬁces. Nicotine replacement therapy was hardly prescribed at 
all. Dentists have a positive attitude towards tobacco cessation interventions and 
